NDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
Priority Review
CAVERJECT (alprostadil) by Pfizer is prostaglandin receptor agonists [moa]. Approved for peripheral arterial occlusive disease, erectile dysfunction. First approved in 1995.
Drug data last refreshed 19h ago
Mechanism of Action
Prostaglandin Receptor Agonists
Pharmacologic Class:
Prostaglandin Analog
Indications (2)
Clinical Trials (5)
Users Study Of The Caverject Delivery System
Started Mar 2013
48 enrolled
Healthy
Caverject User Study
Started Feb 2011
48 enrolled
Erectile Dysfunction
Alprostadil in Maculopathy Study (AIMS)
Started Jul 2006
37 enrolled
Macular Degeneration
Topical Alprostadil for Female Sexual Arousal Disorder
Started Sep 2004
300 enrolled
Sexual Dysfunction, Physiological
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease
Worked on CAVERJECT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.